LTRN vs ACXP Comparison

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.